FY2025 · ended Dec 31, 2025 · Revenue $18,278, +44.3% YoY · Filed Apr 14, 2026
BioAdaptives Inc. (BDPT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $18,278 and a net loss of $1.6 million. Free cash flow was -$534,025.
Revenue (TTM)
$25,561
+694.1% vs year-ago TTM
Net income (TTM)
$-1.16M
-52.2% vs year-ago TTM
Operating cash flow (TTM)
$-436,361
-19.3% vs year-ago TTM
Free cash flow (TTM)
$-436,361
EPS (TTM)
$-0.01
Dividend per share
None
Shares outstanding
12.01M
+32.7% vs prior year
Net cash
—
Operating margin
-3557.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BDPT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1575142
- Former names
- APEX 8 Inc. (until Aug 19, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $18,278 | $12,669 | $28,565 | $17,176 | $19,776 |
| Operating income | -$1.0M | -$602,090 | -$228,921 | — | — |
| Net income | -$1.6M | -$899,161 | -$712,466 | -$895,570 | -$1.0M |
| Diluted EPS | -$0.15 | — | — | — | — |
| Operating cash flow | -$516,025 | -$249,517 | -$223,773 | -$227,259 | -$158,651 |
| Free cash flow | -$534,025 | — | — | — | — |
| Total assets | $225,901 | $261,885 | $103,998 | $37,314 | $148,585 |
| Total liabilities | $2.4M | $1.7M | $1.8M | $1.5M | $1.2M |
| Stockholders' equity | -$2.1M | -$1.5M | -$1.6M | -$1.5M | -$1.1M |
| Cash and investments | $215,205 | $261,885 | $88,557 | $82,978 | $190 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 4, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 14, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 176 BioAdaptives Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.